including diagnostic criteria and management of acute exacerbation of CB (AECB) in the elderly patient.

“Right now, people with bronchiectasis have no approved treatments to prevent pulmonary exacerbations that define this disease and can lead to destruction of lung tissue, putting hundreds of ...

Macrolide maintenance therapy in patients with bronchiectasis significantly reduces the risk for major adverse cardiovascular events.

In bronchiectasis, the walls of the airways become thickened and damaged as a result of a cycle of inflammation and infections. It is characterised by repeated exacerbations or attacks ...

The phase 3 trial achieved a statistically significant reduction in the frequency of exacerbations in patients with bronchiectasis, a serious, chronic lung disease with no approved treatment that ...

Bronchiectasis is a chronic lung disease ... both strengths of brensocatib significantly prolonged the time to first exacerbation and increased the odds of remaining exacerbation-free.

Permanent changes such as bronchiectasis may persist ... with moderate doses of inhaled corticosteroids and has had two exacerbations over the past 3 years requiring oral steroids Case 3: A ...

Professor David Denning evaluates timely and accurate diagnosis of Aspergillus infection and the clinical spectrum of ...

With the FDA granting a priority review to the NDA, a decision from the regulatory body is expected on Aug. 12, 2025. If approved, brensocatib will become the first and only approved treatment for ...